<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915525</url>
  </required_header>
  <id_info>
    <org_study_id>191622-096</org_study_id>
    <nct_id>NCT00915525</nct_id>
  </id_info>
  <brief_title>Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the long term safety and effectiveness of botulinum
      toxin type A in treating patients with idiopathic overactive bladder with urinary
      incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
    <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
    <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
    <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
    <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
    <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
    <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With a Positive Response on the 4-Point Treatment Benefit Scale (TBS)</measure>
    <time_frame>Week 12 Treatment Cycle 1</time_frame>
    <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either &quot;greatly improved&quot; or &quot;improved&quot; are considered to have a positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With a Positive Response on the 4-Point TBS</measure>
    <time_frame>Week 12 Treatment Cycle 2</time_frame>
    <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either &quot;greatly improved&quot; or &quot;improved&quot; are considered to have a positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With a Positive Response on the 4-Point TBS</measure>
    <time_frame>Week 12 Treatment Cycle 3</time_frame>
    <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either &quot;greatly improved&quot; or &quot;improved&quot; are considered to have a positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With a Positive Response on the 4-Point TBS</measure>
    <time_frame>Week 12 Treatment Cycle 4</time_frame>
    <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either &quot;greatly improved&quot; or &quot;improved&quot; are considered to have a positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With a Positive Response on the 4-Point TBS</measure>
    <time_frame>Week 12 Treatment Cycle 5</time_frame>
    <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either &quot;greatly improved&quot; or &quot;improved&quot; are considered to have a positive response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With a Positive Response on the 4-Point TBS</measure>
    <time_frame>Week 12 Treatment Cycle 6</time_frame>
    <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either &quot;greatly improved&quot; or &quot;improved&quot; are considered to have a positive response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Micturition Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
    <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Micturition Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
    <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Micturition Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
    <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Micturition Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
    <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Micturition Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
    <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Daily Average Number of Micturition Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
    <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Urinary Incontinence-Specific Quality of Life (I-QOL) Questionnaire Total Summary Score</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
    <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
    <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
    <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
    <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
    <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
    <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the King's Health Questionnaire (KHQ) Role Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Role Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Role Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Role Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Role Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Role Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Social Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Social Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Social Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Social Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Social Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the KHQ Social Limitations Domain</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
    <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in Daily Frequency of Urgency Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
    <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in Daily Frequency of Urgency Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
    <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in Daily Frequency of Urgency Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
    <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in Daily Frequency of Urgency Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
    <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in Daily Frequency of Urgency Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
    <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in Daily Frequency of Urgency Episodes</measure>
    <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
    <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">829</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>botulinum toxin Type A 100U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin Type A 150U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin Type A</intervention_name>
    <description>Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
    <arm_group_label>botulinum toxin Type A 100U</arm_group_label>
    <arm_group_label>botulinum toxin Type A 150U</arm_group_label>
    <other_name>BOTOXÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in preceding study 191622-095 (NCT00910845) or 191622-520 (NCT00910520)

        Exclusion Criteria:

          -  Females who are pregnant, nursing or planning a pregnancy

          -  Patient has any condition or situation which, in the Investigators opinion, would put
             the patient at risk from continuing treatment with botulinum toxin Type A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <results_first_submitted>October 2, 2015</results_first_submitted>
  <results_first_submitted_qc>November 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 18, 2015</results_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a long-term follow-up study that enrolled patients after participation in the preceding studies 191622-095 (NCT00910845) and 191622-520 (NCT00910520). A total of 829 patients received at least 1 BOTOX treatment in Study 191622-096 or in the preceding studies.</recruitment_details>
      <pre_assignment_details>Following a planned interim analysis, the protocol was amended to remove the option to escalate to the 150U dose. The dose groups reflect the highest dose received (i.e. 100U BOTOX includes patients who only received 100U throughout the study and 150U BOTOX includes patients who received at least 1 dose of 150U at any time during the study).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Botulinum Toxin Type A 100U</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Botulinum Toxin Type A 150U</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="543"/>
                <participants group_id="P2" count="286"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
                <participants group_id="P2" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Retreat Request &gt;Wk 144 (exclusionary)</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Burden</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>BOTOXâTreated population includes all patients enrolled in 191622-096 who received at least 1 BOTOX treatment in study 191622â096, 191622â095 or 191622â520. Treatment groups reflect highest dose received (100U BOTOX includes patients who received 100U throughout the study and 150U BOTOX includes patients who received at least 1 dose of 150U).</population>
      <group_list>
        <group group_id="B1">
          <title>Botulinum Toxin Type A 100U</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Botulinum Toxin Type A 150U</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="543"/>
            <count group_id="B2" value="286"/>
            <count group_id="B3" value="829"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to 74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â¥75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
        <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
          <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Incontinence Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" spread="3.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle1 (N=812)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.26" spread="3.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
        <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
          <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Incontinence Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" spread="3.685"/>
                    <measurement group_id="O2" value="5.66" spread="3.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle2 (N=597, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.64" spread="3.402"/>
                    <measurement group_id="O2" value="-3.05" spread="3.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
        <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
          <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Incontinence Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" spread="3.380"/>
                    <measurement group_id="O2" value="6.30" spread="4.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle3 (N=372, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.82" spread="3.341"/>
                    <measurement group_id="O2" value="-3.46" spread="3.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
        <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
          <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Incontinence Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" spread="3.463"/>
                    <measurement group_id="O2" value="6.19" spread="4.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle4 (N=264, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.48" spread="3.733"/>
                    <measurement group_id="O2" value="-3.32" spread="3.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
        <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
          <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Incontinence Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.47" spread="3.283"/>
                    <measurement group_id="O2" value="6.43" spread="3.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle5 (N=181, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.34" spread="3.791"/>
                    <measurement group_id="O2" value="-3.58" spread="3.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
        <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes</title>
          <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Incontinence Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" spread="3.238"/>
                    <measurement group_id="O2" value="7.17" spread="4.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle6 (N=136, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" spread="3.493"/>
                    <measurement group_id="O2" value="-3.12" spread="3.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With a Positive Response on the 4-Point Treatment Benefit Scale (TBS)</title>
        <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
        <time_frame>Week 12 Treatment Cycle 1</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Positive Response on the 4-Point Treatment Benefit Scale (TBS)</title>
          <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="812"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With a Positive Response on the 4-Point TBS</title>
        <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
        <time_frame>Week 12 Treatment Cycle 2</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Positive Response on the 4-Point TBS</title>
          <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="594"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With a Positive Response on the 4-Point TBS</title>
        <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
        <time_frame>Week 12 Treatment Cycle 3</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Positive Response on the 4-Point TBS</title>
          <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1"/>
                    <measurement group_id="O2" value="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With a Positive Response on the 4-Point TBS</title>
        <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
        <time_frame>Week 12 Treatment Cycle 4</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Positive Response on the 4-Point TBS</title>
          <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With a Positive Response on the 4-Point TBS</title>
        <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
        <time_frame>Week 12 Treatment Cycle 5</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Positive Response on the 4-Point TBS</title>
          <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.2"/>
                    <measurement group_id="O2" value="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With a Positive Response on the 4-Point TBS</title>
        <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
        <time_frame>Week 12 Treatment Cycle 6</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Positive Response on the 4-Point TBS</title>
          <description>The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either âgreatly improvedâ or âimprovedâ are considered to have a positive response.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9"/>
                    <measurement group_id="O2" value="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
        <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
          <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.70" spread="3.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle1 (N=812)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" spread="2.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
        <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
          <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.83" spread="3.634"/>
                    <measurement group_id="O2" value="11.48" spread="3.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle2 (N=597, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="3.037"/>
                    <measurement group_id="O2" value="-2.31" spread="3.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
        <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
          <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.65" spread="3.553"/>
                    <measurement group_id="O2" value="12.22" spread="3.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle3 (N=372, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.86" spread="3.058"/>
                    <measurement group_id="O2" value="-3.01" spread="3.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
        <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
          <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.68" spread="3.456"/>
                    <measurement group_id="O2" value="11.82" spread="3.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle4 (N=264, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.69" spread="3.485"/>
                    <measurement group_id="O2" value="-2.78" spread="2.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
        <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
          <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.55" spread="3.261"/>
                    <measurement group_id="O2" value="11.79" spread="2.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle5 (N=181, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" spread="3.181"/>
                    <measurement group_id="O2" value="-3.19" spread="2.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
        <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Daily Average Number of Micturition Episodes</title>
          <description>The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.85" spread="3.377"/>
                    <measurement group_id="O2" value="11.81" spread="2.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle6 (N=136, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="3.153"/>
                    <measurement group_id="O2" value="-2.66" spread="3.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Urinary Incontinence-Specific Quality of Life (I-QOL) Questionnaire Total Summary Score</title>
        <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Urinary Incontinence-Specific Quality of Life (I-QOL) Questionnaire Total Summary Score</title>
          <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" spread="18.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle1 (N=810)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" spread="24.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</title>
        <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</title>
          <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" spread="18.72"/>
                    <measurement group_id="O2" value="32.8" spread="17.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle2 (N=586, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="24.38"/>
                    <measurement group_id="O2" value="21.6" spread="23.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</title>
        <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</title>
          <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" spread="18.21"/>
                    <measurement group_id="O2" value="31.9" spread="18.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle3 (N=371, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="22.39"/>
                    <measurement group_id="O2" value="23.7" spread="25.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</title>
        <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</title>
          <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="17.32"/>
                    <measurement group_id="O2" value="32.5" spread="19.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle4 (N=261, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="24.90"/>
                    <measurement group_id="O2" value="20.3" spread="22.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</title>
        <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</title>
          <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" spread="17.49"/>
                    <measurement group_id="O2" value="31.9" spread="20.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle5 (N=178, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="23.75"/>
                    <measurement group_id="O2" value="19.5" spread="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</title>
        <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the I-QOL Questionnaire Total Summary Score</title>
          <description>The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="17.87"/>
                    <measurement group_id="O2" value="30.2" spread="20.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle5 (N=178, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="24.99"/>
                    <measurement group_id="O2" value="18.3" spread="14.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Kingâs Health Questionnaire (KHQ) Role Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Kingâs Health Questionnaire (KHQ) Role Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" spread="28.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle1 (N=813)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" spread="34.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Role Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Role Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" spread="28.51"/>
                    <measurement group_id="O2" value="66.2" spread="30.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle2 (N=585, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.1" spread="34.29"/>
                    <measurement group_id="O2" value="-29.2" spread="35.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Role Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Role Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7" spread="28.36"/>
                    <measurement group_id="O2" value="63.4" spread="30.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle3 (N=373, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.7" spread="33.47"/>
                    <measurement group_id="O2" value="-27.9" spread="34.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Role Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Role Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" spread="27.65"/>
                    <measurement group_id="O2" value="62.3" spread="31.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle4 (N=261, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.9" spread="33.82"/>
                    <measurement group_id="O2" value="-23.4" spread="33.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Role Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Role Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" spread="29.15"/>
                    <measurement group_id="O2" value="62.6" spread="31.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle5 (N=179, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.8" spread="35.13"/>
                    <measurement group_id="O2" value="-26.3" spread="28.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Role Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Role Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="30.00"/>
                    <measurement group_id="O2" value="60.3" spread="33.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle6 (N=134, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.8" spread="38.93"/>
                    <measurement group_id="O2" value="-22.9" spread="25.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" spread="30.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle1 (N=813)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.4" spread="29.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" spread="30.96"/>
                    <measurement group_id="O2" value="48.4" spread="30.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle2 (N=585, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0" spread="29.12"/>
                    <measurement group_id="O2" value="-19.0" spread="28.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" spread="31.02"/>
                    <measurement group_id="O2" value="45.4" spread="31.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle3 (N=373, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.9" spread="29.26"/>
                    <measurement group_id="O2" value="-19.2" spread="28.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="31.86"/>
                    <measurement group_id="O2" value="43.2" spread="30.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle4 (N=261, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.8" spread="31.26"/>
                    <measurement group_id="O2" value="-16.1" spread="23.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" spread="31.39"/>
                    <measurement group_id="O2" value="43.4" spread="32.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle5 (N=179, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.7" spread="28.47"/>
                    <measurement group_id="O2" value="-15.7" spread="24.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
        <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the KHQ Social Limitations Domain</title>
          <description>The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="32.72"/>
                    <measurement group_id="O2" value="43.3" spread="32.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle6 (N=134, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" spread="33.59"/>
                    <measurement group_id="O2" value="-17.6" spread="24.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
        <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 1</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
          <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.55" spread="4.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle1 (N=812)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.81" spread="4.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
        <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 2</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
          <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.63" spread="4.188"/>
                    <measurement group_id="O2" value="9.09" spread="4.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle2 (N=597, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.07" spread="4.046"/>
                    <measurement group_id="O2" value="-3.96" spread="4.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
        <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 3</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
          <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.62" spread="4.055"/>
                    <measurement group_id="O2" value="9.28" spread="4.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle3 (N=372, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.22" spread="4.120"/>
                    <measurement group_id="O2" value="-3.86" spread="4.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
        <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 4</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
          <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="3.951"/>
                    <measurement group_id="O2" value="8.98" spread="4.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle4 (N=264, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.92" spread="4.341"/>
                    <measurement group_id="O2" value="-3.50" spread="3.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
        <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 5</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
          <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.67" spread="3.961"/>
                    <measurement group_id="O2" value="8.89" spread="3.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle5 (N=181, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.11" spread="4.549"/>
                    <measurement group_id="O2" value="-3.56" spread="3.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
        <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
        <time_frame>Study Baseline, Week 12 Treatment Cycle 6</time_frame>
        <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 100U</title>
            <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 150U</title>
            <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in Daily Frequency of Urgency Episodes</title>
          <description>The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).</description>
          <population>BOTOX-Treated Population: all patients with data at the time point who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520); analyses are based on actual treatment received</population>
          <units>Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.98" spread="4.059"/>
                    <measurement group_id="O2" value="8.84" spread="3.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chg from Study BL at Wk 12 Tmt Cycle6 (N=136, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.95" spread="4.662"/>
                    <measurement group_id="O2" value="-2.64" spread="4.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>BOTOX-Treated Population includes all patients who received at least 1 BOTOX treatment since the start of their clinical study participation (in study 191622-096, 191622-095 or 191622-520), and is used to assess adverse events (AEs) and serious adverse events (SAEs). AEs and SAEs are reported by treatment cycle.</desc>
      <group_list>
        <group group_id="E1">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 1</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 2</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Botulinum Toxin Type A 150U Treatment Cycle 2</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 3</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Botulinum Toxin Type A 150U Treatment Cycle 3</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 4</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Botulinum Toxin Type A 150U Treatment Cycle 4</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 5</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Botulinum Toxin Type A 150U Treatment Cycle 5</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E10">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 6</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E11">
          <title>Botulinum Toxin Type A 150U Treatment Cycle 6</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E12">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 7</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E13">
          <title>Botulinum Toxin Type A 150U Treatment Cycle 7</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E14">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 8</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E15">
          <title>Botulinum Toxin Type A 150U Treatment Cycle 8</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E16">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 9</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E17">
          <title>Botulinum Toxin Type A 150U Treatment Cycle 9</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E18">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 10</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E19">
          <title>Botulinum Toxin Type A 150U Treatment Cycle 10</title>
          <description>Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E20">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 11</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E21">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 12</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
        <group group_id="E22">
          <title>Botulinum Toxin Type A 100U Treatment Cycle 13</title>
          <description>Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stress Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mitral Valve Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Foramen Magnum Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Congenital Diaphragmatic Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vitreous Floaters</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Crohnâs Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Internal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Large Intestine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Enterovesical Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Medical Device Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Device Ineffective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Allergy to Plants</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anaphylactic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Appendiceal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infected Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Comminuted Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stress Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Incisional Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Forearm Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Radiation Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Sigmoidoscopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Heart Rate Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Obesity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tendon Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Breast Cancer Stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Invasive Ductal Breast Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lung Carcinoma Cell Type Unspecified Stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <description>MALE ONLY</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <description>FEMALE ONLY</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="553"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Benign Neoplasm of Spinal Cord</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thyroid Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyogenic Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Benign Ovarian Tumour</sub_title>
                <description>FEMALE ONLY</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="553"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lip Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma in Situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>B-Cell Small Lymphocytic Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma of Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bulbar Palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Obturator Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Restless Legs Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cerebral Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cervical Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peroneal Nerve Palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Depression Suicidal</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urge Incontinence</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cystitis Interstitial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hydroureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pelvi-Ureteric Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <description>MALE ONLY</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Polycystic Ovaries</sub_title>
                <description>FEMALE ONLY</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="553"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <description>FEMALE ONLY</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="553"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vaginal Prolapse</sub_title>
                <description>FEMALE ONLY</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="553"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cervical Polyp</sub_title>
                <description>FEMALE ONLY</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="553"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <description>FEMALE ONLY</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="553"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <description>FEMALE ONLY</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="553"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Endometrial Hypertrophy</sub_title>
                <description>FEMALE ONLY</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="749"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="553"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Atopic</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Swelling Face</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Excessive skin</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin Wrinkling</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Preventive Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arterial Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Temporal Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="297" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="135" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="86" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="34" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="53" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="35" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="43" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="37" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="21" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="18" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Eye Inflammation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Capsular Contracture Associated with Breast Implant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="107" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="67" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="40" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="20" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="28" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="24" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="13" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Radiation Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Residual Urine Volume</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cervical Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Neoplasm of Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Trigeminal Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cystitis Glandularis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bladder Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urine Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>MALE ONLY</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <description>MALE ONLY</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Swelling Face</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin Wrinkling</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="829"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="608"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

